Orchestra BioMed Secures $110M Funding to Accelerate Global Innovation in Cardiovascular Therapies

Orchestra BioMed (Nasdaq: OBIO) is thrilled to announce a significant milestone in its journey of biomedical innovation, having raised $110 million in its latest funding round. This substantial capital infusion is aimed at accelerating the company’s mission to bring high-impact technologies to patients worldwide through its unique risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed is renowned for its strategic collaborations with industry titans such as Medtronic and Terumo, which have been instrumental in the global commercialization of its breakthrough therapeutic solutions. The new funds will primarily support the clinical and regulatory advancement of Orchestra BioMed’s promising lead product candidate—atrioventricular interval modulation (AVIM) therapy, also known as BackBeat Cardiac Neuromodulation Therapy (CNT™)—designed for the treatment of hypertension, a critical risk factor that contributes significantly to global mortality rates. In addition, the investment will help drive further development of the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for treating atherosclerotic artery disease, enabling Orchestra BioMed to tackle some of the world’s most pressing cardiovascular health challenges. This funding not only reinforces the company’s commitment to advancing late-stage clinical research and achieving regulatory approvals but also positions it to expand its product pipeline through potential acquisitions, strategic collaborations, and organic development. As Orchestra BioMed continues to leverage its expertise and the strong foundation provided by its partners, the new capital will be critical in enhancing global patient access to transformative medical technologies and driving sustainable growth in the evolving landscape of medical innovation. For more information, please visit www.orchestrabiomed.com.